Capital Markets Day: Commercial Execution and Innovation in Obesity Care
5
Commercial execution and innovation
Obesity care
Patient-centric strategy designed to activate more people with
obesity, drive HCP engagement and improve market access
Millon
people >650 million people
650
live with obesity
50
50
650
0
-10% seek help
~2% are treated
with an AOM
~2.5 million seen by
obesity experts
Treated ~1 million
55
65
with SaxendaⓇ in
2021
Only 25% on treatment
for more than 1 year
13
-2.5———
-1
0.25
Ensure obesity is a healthcare priority
needing medical management
Maximize the value of Novo Nordisk's
superior treatment solutions
People with obesity
activation
HCP
engagement
Value proposition
to payers
Marketed product portfolio and pipeline
closing the treatment gaps
HCP: Healthcare providers; AOM: Anti-obesity medication
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation